Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis

NCT01969409 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Ambulatory IPF

Interventions

DRUG: Rituximab
DRUG: Placebo

Sponsor

University of Alabama at Birmingham

Collaborators

[object Object]